Last reviewed · How we verify
ER OROS paliperidone, paliperidone ER
ER OROS paliperidone, paliperidone ER is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 1 development.
At a glance
| Generic name | ER OROS paliperidone, paliperidone ER |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ER OROS paliperidone, paliperidone ER CI brief — competitive landscape report
- ER OROS paliperidone, paliperidone ER updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about ER OROS paliperidone, paliperidone ER
What is ER OROS paliperidone, paliperidone ER?
ER OROS paliperidone, paliperidone ER is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Who makes ER OROS paliperidone, paliperidone ER?
ER OROS paliperidone, paliperidone ER is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).
What development phase is ER OROS paliperidone, paliperidone ER in?
ER OROS paliperidone, paliperidone ER is in Phase 1.